XM does not provide services to residents of the United States of America.
H
H

Hikma

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Hikma Completes Xellia Acquisition

BRIEF-Hikma Completes Xellia Acquisition Sept 10 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HIKMA PHARMACEUTICAL - HIKMA COMPLETES XELLIA ACQUISITION Source text for Eikon: ID:nRSJ5017Da Further company coverage: HIK.L
H

US allows increased production of Takeda's ADHD drug and its generics to address shortage

CORRECTED-US allows increased production of Takeda's ADHD drug and its generics to address shortage Corrects headline and paragraph 1 to make clear Takeda's drug is not in shortage Sept 4 (Reuters) - The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's 4502.T ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the copies in the United States.
H
T

Draegerwerk, Hikma, Novartis

EUROPE RESEARCH ROUNDUP-Draegerwerk, Hikma, Novartis Sept 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Draegerwerk, Hikma and Novartis, on Tuesday. HIGHLIGHTS * Draegerwerk DRWG.DE : Jefferies raises to hold from underperform * Hikma HIK.L : Berenberg raises to buy from hold * Munters Group AB MTRS.ST : Jefferies raises to buy from hold * Novartis AG NOVN.S : Jefferies cuts to hold from buy * Swedencare AB (Publ) SECARE.ST : J
A
A
A
B
B
B
C
D
G
H
H
N
S
T
U
A
P

Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug

Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug By Mike Scarcella Aug 27 (Reuters) - Drug companies Jazz JAZZ.O and Hikma HIK.L must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing health plans to pay higher prices, a U.S. judge in California has ruled. U.S. District Judge Richard Seeborg’s ruling on Monday night in San Francisco cleared a path to trial on some claims in the long-running multidistrict legal act
H

Danske Bank, Lotus Bakeries NV, Vesuvius

EUROPE RESEARCH ROUNDUP-Danske Bank, Lotus Bakeries NV, Vesuvius Aug 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Lotus Bakeries NV and Vesuvius, on Tuesday. HIGHLIGHTS * Abrdn Plc ABDN.L : Morgan Stanley raises target price to 160p from 149p * Danske Bank DANSKE.CO : Morgan Stanley initiates coverage with overweight rating * Lotus Bakeries NV LOTB.BR : Berenberg raises target price to EUR 10,300 from EUR 9,000 *
A
A
A
B
C
D
E
F
H
H
K
L
M
M
N
O
S
S
S
S
S
H
A
S
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.